On August 29, 2025, the International Cooperation Department of the China Securities Regulatory Commission issued a filing notice for Xuanzhu Biotech Co., Ltd.'s overseas issuance and listing and domestic unlisted shares "full circulation" (Notice No. Guo He Han [2025] 1470).

According to the filing notice, Xuanzhu Biology plans to issue no more than 77.4335 million overseas listed ordinary shares and list on the Hong Kong Stock Exchange. Additionally, 17 shareholders plan to convert a total of 93.368496 million domestic unlisted shares they hold into overseas listed shares.

Xuanzhu Biology submitted prospectuses to the Hong Kong Stock Exchange twice on November 25, 2024 and June 13, 2025, with CICC and CMB International serving as joint sponsors.

Xuanzhu Biology is headquartered in Beijing, registered in Shijiazhuang, Hebei, and was spun off from SIHUAN PHARM (00460.HK). As an innovation-driven Chinese biopharmaceutical company with global vision, the company has established a comprehensive internal R&D platform to support the development of a highly competitive and balanced pipeline.

As of the last practicable date, Xuanzhu Biology has more than ten drug assets under active development, covering digestive system diseases, tumors and non-alcoholic steatohepatitis (NASH). These include two NDA approved assets, two drug projects in NDA registration stage, four drug projects in Phase I clinical trial stage, and five with IND approval.

Xuanzhu Biology prospectus link: https://www1.hkexnews.hk/app/sehk/2025/107438/documents/sehk25061301829_c.pdf